Compositions and methods for the treatment of muscle wasting
First Claim
1. A method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount of a composition suitable for administration to an animal comprisinga modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5′
- to 3′
internucleoside phosphate linkages,wherein the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5′
UTR region, translational start site, the 3′
UTR, and translational termination site, andwherein the gene encodes FOXO1.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the treatment of muscle wasting conditions and/or the promotion of muscle growth.
-
Citations
13 Claims
-
1. A method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount of a composition suitable for administration to an animal comprising
a modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5′ - to 3′
internucleoside phosphate linkages,wherein the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5′
UTR region, translational start site, the 3′
UTR, and translational termination site, andwherein the gene encodes FOXO1. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- to 3′
-
2. A method of promoting muscle growth in an individual comprising administering to the individual an effective amount of a composition suitable for administration to an animal comprising
a modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5′ - to 3′
internucleoside phosphate linkages,wherein the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5′
UTR region, translational start site, the 3′
UTR, and translational termination site, andwherein the gene encodes FOXO1. - View Dependent Claims (13)
- to 3′
Specification